Bellicum Pharmaceuticals (NASDAQ:BLCM) Rating Increased to Hold at Zacks Investment Research

Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Friday, Zacks.com reports.

According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. “

A number of other research analysts have also weighed in on BLCM. LADENBURG THALM/SH SH assumed coverage on Bellicum Pharmaceuticals in a report on Wednesday, February 16th. They set a “buy” rating and a $5.00 price objective on the stock. StockNews.com assumed coverage on Bellicum Pharmaceuticals in a research report on Friday, May 13th. They set a “sell” rating on the stock. Finally, TheStreet downgraded Bellicum Pharmaceuticals from a “c-” rating to a “d-” rating in a research report on Friday, April 8th.

Shares of NASDAQ:BLCM traded down $0.09 during trading on Friday, reaching $1.46. The company had a trading volume of 17,908 shares, compared to its average volume of 44,513. The stock’s fifty day moving average price is $1.80 and its 200 day moving average price is $1.71. Bellicum Pharmaceuticals has a fifty-two week low of $1.34 and a fifty-two week high of $4.04. The firm has a market capitalization of $12.57 million, a price-to-earnings ratio of -5.03 and a beta of 1.46.

Bellicum Pharmaceuticals (NASDAQ:BLCMGet Rating) last announced its quarterly earnings data on Thursday, March 24th. The biopharmaceutical company reported ($0.27) earnings per share for the quarter. The company had revenue of $0.50 million during the quarter. On average, equities research analysts expect that Bellicum Pharmaceuticals will post -1.82 EPS for the current fiscal year.

A hedge fund recently raised its stake in Bellicum Pharmaceuticals stock. Geode Capital Management LLC grew its position in shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCMGet Rating) by 30.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 76,533 shares of the biopharmaceutical company’s stock after acquiring an additional 17,874 shares during the quarter. Geode Capital Management LLC owned about 0.91% of Bellicum Pharmaceuticals worth $223,000 at the end of the most recent quarter. Institutional investors and hedge funds own 28.09% of the company’s stock.

About Bellicum Pharmaceuticals (Get Rating)

Bellicum Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens.

Featured Articles

Get a free copy of the Zacks research report on Bellicum Pharmaceuticals (BLCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.